The Justice Department has reclassified state-licensed medical marijuana from Schedule I to Schedule III under federal law, marking a major shift in U.S. marijuana policy. In this interview, attorney and cannabis policy advocate David Holland explains what the change means in practical terms, including how it could affect medical research, state cannabis programs and marijuana-related businesses. The conversation also breaks down what this does and does not do, including why this is not full federal legalization and what questions still remain about interstate commerce, regulation and adult-use markets.